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Abstract To test the hypothesis that the non-enzymatic
reaction of quinones with thiols in plasma can generate reactive
oxygens (ROS), thereby leading to potentiated cellular toxicity,
we have studied the effect of a representative quinone compound,
menadione, on plasma isolated from rats. The experimental
results are as follows: (1) menadione generated ROS via non-
enzymatic reaction with protein thiols in plasma; (2) the presence
of plasma increased menadione-induced cytotoxicity to platelets ;
(3) pretreatment of plasma with a thiol-depleting agent
significantly suppressed menadione-induced ROS and cytotoxi-
city. These results suggest that the non-enzymatic reaction of
menadione with plasma thiols could be an important process in
quinone-induced cellular toxicity.
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1. Introduction
Oxidative stress is de¢ned as a disturbance in the prooxi-
dant-antioxidant balance in favor of the former, leading to
potential damage [1]. It has been reported that oxidative stress
is related to such chronic diseases as atherosclerosis, cancer,
and diabetes mellitus. Oxidants causing oxidative stress can be
generated endogenously, by immune cells such as neutrophils,
and exogenously, by exposure to drugs [2,3]. Menadione (2-
methyl-1,4-naphthoquinone: vitamin K3), a multivitamin
component and a widely used therapeutic agent for hypoth-
rombinemia and cancer, is cytotoxic in isolated hepatocytes
and its cytotoxic mechanism has been associated with the
excessive generation of reactive oxygens such as superoxide,
singlet oxygen, and hydrogen peroxide. Menadione is metab-
olized to a semiquinone by various £avoenzymes, such as
NADPH cytochrome P-450 reductase, NADH cytochrome
b5 reductase, and NADH-ubiquinone reductase. This semiqui-
none is converted to the parent quinone in the presence of
oxygen, thereby generating reactive superoxides which play a
critical role in cellular oxidative damage [4^6].
It has also been reported that menadione is converted to the
semiquinone by non-enzymatic reaction with various thiols. In
the presence of oxygen, reactive oxygens are generated by this
non-enzymatic reaction in the test tube [7^10]. This mena-
dione-thiol reaction has also been observed both in hepatic
microsomal systems and within intact cells (hepatocytes). In
liver microsomes, superoxide was generated in the absence of
NAD(P)H, a cofactor required for enzymatic reduction of
menadione, and the generation of superoxide was blocked
by N-ethylmaleimide (NEM), a thiol-depleting agent [11]. In
isolated hepatocytes, formation of GSSG, which is indicative
of oxidative stress, is increased in the absence of NAD(P)H
[12]. Wefers and Sies [13] also reported that, in menadione-
treated hepatocytes, less singlet oxygen could be detected in
GSH-depleted hepatocytes than in control (non-GSH-de-
pleted) hepatocytes, suggesting that non-enzymatic reaction
of menadione with soluble thiol (GSH) has biological rele-
vance in the cell. However, they also observed that the reac-
tion of menadione and GSH catalyzed by a detoxi¢cation
enzyme, glutathione S-transferase (GST), was not accompa-
nied by the generation of reactive oxygens. Therefore, though
menadione can be reacted with thiols non-enzymatically in the
cell following the generation of reactive oxygens, the biolog-
ical implication of this observation is currently unclear, given
the relatively high intracellular activity of GST [14].
Blood plasma provides important transport functions, so
plasma is readily exposed to various drugs or chemicals. Plas-
ma is rich in protein thiols, but has only a limited amount of
soluble thiol (including GSH) [15]. In addition, the activity of
GST is negligible in plasma [14]. Thus we can assume that the
non-enzymatic reaction of menadione with protein thiols fol-
lowing the generation of reactive oxygens is a major process
of menadione in plasma, which could lead to cellular toxicity.
This paper addresses that issue by showing that menadione
reacts with plasma thiols, thereby generating reactive oxygens.
In addition, we observed that the presence of plasma a¡ected
toxicity of menadione to adjacent cells such as platelets, the
cells directly exposed to plasma.
2. Materials and methods
2.1. Materials
The following reagents were obtained from Sigma (St. Louis, MO,
USA): menadione, NEM, dimethyl sulfoxide (DMSO), superoxide
dismutase (SOD), catalase, and 5,5P-dithiobis (2-nitrobenzoic acid)
(DTNB). All other reagents were commercial products of the highest
available grade of purity.
2.2. Animals
Female Sprague-Dawley rats (180^220 g) were used for all experi-
ments. The animals were maintained at 22 þ 2‡C and 45^55% humid-
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ity under a 12 h light-dark cycle. The animals were allowed food and
water ad libitum.
2.3. Preparations of plasma, platelet-rich plasma, or washed platelets
All procedures were conducted at room temperature, and the use of
glass containers and pipettes was avoided. Blood was collected from
the abdominal aorta of ether-anesthetized rats. For plasma prepara-
tion, 3.8% sodium citrate (1:9) was used as an anticoagulant. Plasma
was obtained by centrifugation at 1500Ug for 20 min. ‘Filtered plas-
ma’ was prepared by ¢ltering plasma through Centriprep 50 (Amicon,
USA), thereby eliminating proteins higher than 50 000 Da from the
plasma. ‘Boiled plasma’ was prepared by heating plasma in a test tube
in boiling water for 30 s. For the preparation of platelet-rich plasma
(PRP) or washed platelets (WP), acid-citrate-dextrose (ACD) (1:6;
85 mM trisodium citrate, 71 mM citric acid, 111 mM dextrose) was
used as an anticoagulant. ACD blood was centrifuged at 150Ug for
15 min to obtain condensed PRP. The platelets were pelleted by cen-
trifugation at 500Ug for 10 min. Platelets were washed in washing
bu¡er (138 mM NaCl, 2.8 mM KCl, 0.8 mM KH2PO4, 0.8 mM
MgCl2, 10 mM HEPES, 5.6 mM dextrose, 2 mM EDTA, pH 7.4)
and pelleted by centrifugation at 500Ug for 10 min. Final platelet
pellets were resuspended in plasma for PRP or in suspension bu¡er
for WP. The composition of WP suspension bu¡er was 138 mM
NaCl, 2.8 mM KCl, 0.8 mM KH2PO4, 0.8 mM MgCl2, 10 mM
HEPES, 5.6 mM dextrose, pH 7.4. For all experiments, the platelet
concentration was adjusted to 5U108 cells/ml using light microscopy.
Whole plasma, PRP or WP were incubated at 37‡C in plastic £asks.
Menadione was added as a 0.5% solution in DMSO; controls received
vehicle alone. Aliquots were withdrawn for analysis after various time
intervals.
2.4. Biochemical assays
Oxygen consumption was measured polarographically with a Clark
oxygen electrode (Yellow Springs Instrument Co., USA) in magneti-
cally stirred sample chambers at 37‡C. Whole plasma, PRP or WP
were preincubated under the same conditions for at least 5 min to
saturate samples with air. The initial rate of oxygen consumption was
determined from the time of addition of menadione or DMSO alone
through 3 min post treatment. Treatments are indicated in the ¢gure
legends.
Total plasma thiol concentration was measured by the method de-
scribed by Hu [16]. In short, an aliquot (50 Wl) of plasma was mixed
with 1.0 ml of Tris-EDTA bu¡er (250 mM Tris base, 20 mM EDTA,
pH 8.2), and to this 20 Wl of DTNB stock solution (10 mM in abso-
lute methanol) was added. DTNB reacts with plasma thiol to produce
a highly colored anion with maximum absorption at 412 nm
(O412 = 13 600 M31 cm31). Sulfhydryl group (total plasma thiols) con-
centration was determined after correction using an appropriate
blank.
The viability of platelets was monitored by release of lactate de-
hydrogenase (LDH) following separation of cells from incubation
bu¡er by centrifugation at 10 000Ug for 2 min, as described previ-
ously [17].
3. Results
3.1. The generation of reactive oxygens via non-enzymatic
reaction of menadione and plasma thiols
To determine whether reactive oxygens can be generated by
menadione in plasma, we measured menadione-induced oxy-
gen consumption in plasma (Fig. 1). When 0.25 mM mena-
dione was added to plasma, oxygen consumption increased
slowly through the 10 min incubation period. Treatment
with 1 mM menadione resulted in increased oxygen consump-
tion through 5 min, at which time oxygen consumption was
maximal. When plasma was treated with the control vehicle,
DMSO, no increase in oxygen consumption was observed.
Addition of superoxide dismutase (SOD) and catalase at
3 min before menadione addition resulted in a signi¢cant re-
duction of menadione-induced oxygen consumption in plas-
ma. These results suggest that menadione causes increased
oxygen consumption in plasma, which is due to the generation
of reactive oxygens.
It was assumed that the menadione-induced generation of
reactive oxygens was due to the reaction of menadione with
thiols in the plasma according to previous reports [7^10]. To
test this assumption, we investigated whether thiols in plasma
were depleted following the reaction of menadione with thiols
(Fig. 2). Plasma treated with 1 mM menadione resulted in
complete depletion of the thiols within 5 min. Treatment
with 0.25 mM menadione resulted in a slower rate of thiol
depletion with incomplete depletion observed even through a
30 min incubation period. These observations are consistent
with the pattern of oxygen consumption in menadione-treated
plasma, depicted in Fig. 1. They con¢rm the assumption that
menadione-induced reactive oxygen generation is mediated by
the reaction of menadione with thiols, as evidenced by the
menadione depletion of plasma thiols.
To con¢rm the role of plasma thiols treated with mena-
dione in the generation of reactive oxygens, we also pretreated
plasma with NEM, a known plasma thiol-depleting agent. As
seen in Fig. 3A, NEM pretreatment of plasma almost com-
pletely blocked the menadione-induced increase in oxygen
consumption. To further characterize the reaction of mena-
dione with thiols in plasma, when ‘¢ltered plasma’ without
proteins higher than 50,000 Da was treated with menadione,
a signi¢cant increase in oxygen consumption by menadione
was not observed (Fig. 3B). This suggests that low molecular
weight components including soluble thiols (glutathione, etc.)
in plasma were not involved in the generation of reactive oxy-
gens in the presence of menadione. However, ‘boiled plasma’
followed by menadione treatment resulted in increased oxygen
consumption approximately equal to that seen in intact plas-
ma, suggesting that the reaction of menadione with high mo-
lecular weight thiols (protein thiols) is non-enzymatic. These
results, taken together with those depicted in Fig. 2, indicate
that menadione can generate reactive oxygens via non-enzy-
Fig. 1. Time course of oxygen consumption induced by menadione
in rat plasma. For plasma preparation, blood was collected from
the abdominal aorta of rats and then centrifuged at 1500Ug for 20
min. Whole plasma was used for the assays for oxygen consumption
as described in Section 2. The arrow indicates the time of mena-
dione addition. The group pretreated with SOD (500 U/ml) and cat-
alase (500 U/ml) 3 min prior to menadione addition is represented
by a dotted curve. Data are from one representative in vitro run;
two other similar in vitro runs were also performed.
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matic reaction with protein thiols in plasma and, as a result,
plasma thiols are decreased.
3.2. Potentiation of the cytotoxic e¡ect of menadione by the
presence of plasma
Menadione cytotoxicity in various tissues and blood cells,
such as erythrocytes, neutrophils, and platelets, is well docu-
mented [4,18]. Since our results indicate that reactive oxygens
are generated by menadione in plasma, we hypothesized that
menadione-induced cytotoxicity to certain tissues might be
in£uenced by the presence of plasma.
To test this hypothesis, we selected a platelet model for the
following reasons: (1) platelets are directly exposed to plas-
ma; (2) platelets are reported to be susceptible to menadione-
induced cytotoxicity; and (3) platelet systems both with plas-
ma (PRP) and without plasma (WP) have been well developed
in extensive platelet research.
In Fig. 4, we pretreated PRP with the thiol-depleting agent
NEM and cytotoxicity as assessed by LDH release was com-
pared to that seen by menadione alone. We hypothesized that
NEM pretreatment would reduce menadione-induced cytotox-
icity to platelets in the PRP system because the protein thiols
would no longer be available for the non-enzymatic reaction
of menadione in plasma. Treatment with NEM alone does not
result in release of LDH from platelets. As previous studies
have shown [19], menadione (0.25 mM) induced LDH release
in a time-dependent manner, such that more than 90% of
LDH activity in platelets is released at 120 min. NEM pre-
treatment, however, signi¢cantly suppressed menadione-in-
duced cytotoxicity, con¢rming our hypothesis that protein
thiols present in plasma play a role in the menadione-induced
cytotoxicity to platelets. We considered the possibility that
NEM itself could interfere with the LDH assay by measuring
known amounts of LDH activity in the presence of a 0.25
mM concentration of NEM used in our experiments. No ef-
fect was observed on LDH activity (data not shown).
To clarify this observation, we compared the cytotoxicity of
menadione in PRP and WP (Fig. 5). One complication which
should be considered was the binding of menadione to plasma
protein which could cause substantial decreases in the concen-
tration of free menadione. To compensate for this e¡ect, we
utilized previously observed data [20], which indicated that the
free menadione concentration in PRP incubation solution
containing 1 mM menadione was equivalent to the free me-
nadione present in WP incubation solution containing 0.25
mM menadione. We therefore compared 1 mM menadione-
treated PRP with 0.25 mM menadione-treated WP, as well as
0.25 mM menadione-treated PRP with 0.25 mM menadione-
treated WP.
Fig. 5A shows a comparison of oxygen consumption rates
of each of these systems. In each system, the control DMSO
treatment caused little or no e¡ect on oxygen consumption
rate, although slight elevations in oxygen consumption were
observed due to the presence of the platelets and their basal
metabolism. As shown in Fig. 1, menadione in plasma (rela-
tively free of cells) resulted in dose-dependent, increased non-
Fig. 2. E¡ect of menadione on total plasma thiols. After incubation
of whole plasma with various doses of menadione, an aliquot (50
Wl) of incubation medium was taken out to measure total plasma
thiol concentration as described in Section 2. Values are means
þ S.E.M. from at least three experiments.
Fig. 3. A: E¡ect of NEM pretreatment on menadione-induced oxy-
gen consumption in rat plasma. For the ‘NEM-treated plasma’
group, whole plasma was preincubated with 10 mM NEM 1 h prior
to addition of menadione at 37‡C. B: Time course of menadione-in-
duced oxygen consumption in ¢ltered or boiled plasma. ‘Filtered
plasma’ was prepared by ¢ltering whole plasma through Centriprep
50 (Amicon, USA) and ‘boiled plasma’ was prepared by stringently
heating whole plasma in a test tube in boiling water for 30 s. The
assays for oxygen consumption were conducted as described in Sec-
tion 2. Arrows (A and B) indicate the time of 1 mM menadione ad-
dition. Data (A and B) are from one representative in vitro run;
two other similar in vitro runs were also performed.
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enzymatic oxygen consumption due to menadione reaction
with plasma thiols. In WP (free of plasma), statistically sig-
ni¢cantly increased oxygen consumption by 0.25 mM mena-
dione was also observed, but 1 mM menadione was not tested
because of its solubility in washing bu¡er. As the menadione-
induced increase in oxygen consumption rate in WP (free of
plasma) was compared with that in PRP, the latter is larger
than the former. This indicated that the presence of plasma
has an additive e¡ect on the increased oxygen consumption
rates induced by the menadione treatments in our model tis-
sue, platelets.
Based on this result, we postulated that the presence of
plasma would also a¡ect menadione-induced cytotoxicity to
platelets. We observed the cytotoxicity of menadione in each
system by measuring LDH release from platelets (Fig. 5B).
Menadione-treated PRP (1 mM and 0.25 mM) showed a dra-
matically faster and greater LDH release than menadione-
treated WP (0.25 mM). The two doses of menadione-PRP
together shown in Fig. 5B indicate that the thiols in the
PRP system must have increased the toxicity of menadione
to some degree. Increased LDH release is observed in PRP
compared to that in WP, even though a nominally equivalent
menadione dose (0.25 mM) is present. The amount of free
menadione in the nominal 0.25 mM menadione-PRP system
is very likely less than 0.25 mM, because it has been shown
that some menadione is bound to the protein in the PRP
system. Despite this, however, the toxic response was in-
creased by using the thiol-containing plasma (PRP) system.
A 1 mM menadione-PRP treatment was also run, because
experiments have shown that the free amount of menadione
in this system is roughly equivalent to that present in the 0.25
mM WP treatment. Even greater and more rapid toxicity is
seen with the 1 mM PRP dose. These LDH release results are
well correlated with the oxygen consumption rates observed in
each system (Fig. 5A) and strongly suggest that menadione-
induced cytotoxicity can be increased by the presence of blood
plasma.
4. Discussion
This investigation has shown that menadione reacts non-
enzymatically with protein thiols in plasma, causing genera-
tion of reactive oxygens. This reaction a¡ects the potency of
menadione toxicity to platelet cells in plasma. Plasma may
serve as a critical component in the expression of menadione
toxicity and a¡ect cells (e.g. immune cells, blood cells) in other
tissues (e.g. bone marrow) exposed to the plasma, as well as in
the vascular system.
We demonstrated that menadione causes increased oxygen
consumption (Fig. 1), which is due to the generation of reac-
tive oxygens by reacting with thiols (Fig. 2 shows depletion of
thiols). The possibility that soluble thiols (e.g. glutathione) in
plasma played an important role in this reaction is very un-
likely because ¢ltered plasma (excluding 50 000 Da molecular
weight protein thiols) did not generate reactive oxygen (Fig. 3).
We also showed that the reaction with protein thiols was non-
enzymatic by demonstrating that menadione in boiled plasma
was still capable of generating reactive oxygens (Fig. 3).
Fig. 4. E¡ect of NEM treatment on menadione-induced cytotoxicity
in PRP. After preincubation of PRP with 250 WM NEM for 30 min
at 37‡C, menadione was added to the incubation medium. The incu-
bation was stopped at the indicated time points, and aliquots were
centrifuged to determine the extent of LDH leakage. Values are
means þ S.E.M. (n = 3).
Fig. 5. A: Initial oxygen consumption rate (from 0 to 2 min) in-
duced by menadione in plasma, WP and PRP. C represents control;
the numbers on the x axis represents the concentration (mM) that
was used. Values are means þ S.E.M. (n = 3). B: LDH release in-
duced by menadione in PRP or WP. Symbols represent menadione
concentration in the respective system: (F) 1 mM menadione in
PRP; (S) 0.25 mM menadione in PRP; (b) 0.25 mM menadione in
WP; (E) PRP control; (a) WP control. Values are means þ S.E.M.
(n = 3).
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In order to demonstrate whether reactive oxygens non-en-
zymatically generated by menadione in plasma could a¡ect
adjacent cells, a platelet system with plasma (PRP) and with-
out plasma (WP) was used. We examined the e¡ect of plasma
by comparing toxicity to platelets using 0.25 mM menadione
in both PRP and WP. In addition, we compared toxicity to
platelets using 1 mM menadione in PRP with 0.25 mM me-
nadione in WP. This comparison was made because our pre-
vious paper [20] demonstrated that the concentration of free
menadione in PRP with 1 mM menadione was equivalent to
that of WP with 0.25 mM menadione. We demonstrated that
greater and more rapid toxicity resulted from 1 mM PRP
(Fig. 5B), even though the amount of free menadione was
equal to that in the WP system.
Many quinone compounds are both naturally occurring
and often used as drugs [2,3]. Like menadione, other quinone
compounds would be able to bind with thiols, thereby result-
ing in the generation of reactive oxygens in physiologically
relevant systems, such as our laboratory’s in vitro platelet
systems (shown by our data) and, of course, in in vivo expo-
sures. Several other representative quinone substances, such as
benzoquinones [21] and many naphthoquinones [22], are re-
ported to be able to form reactive oxygens via the same non-
enzymatic reaction. It is possible that the presence of plasma
would increase the generation of reactive oxygens by these
quinones, thereby a¡ecting their toxicity to adjacent tissues.
Plasma may also enhance the toxicity of non-quinone com-
pounds by similar or di¡erent mechanisms. It was recently
reported that phenylhydrazine-induced toxicity to erythro-
cytes appeared to be increased in the presence of plasma
[23]. The authors, however, did not speculate on the possible
cause for their observations and so the exact mechanism of
phenylhydrazine-induced toxicity and its enhancement by
plasma remains to be identi¢ed.
Most in vitro studies for toxicological drug evaluation are
performed in bu¡er systems. However, our studies revealed
that these in vitro studies using bu¡er could underestimate
in vivo toxicity, if plasma enhances the cytotoxicity of the
drug, as it did for the quinone, menadione, in our study.
Previous studies showed that therapeutic application of me-
nadione induced hemolysis in erythrocytes [24,25], but in vitro
studies required higher concentrations of menadione to induce
hemolysis [26]. Our unpublished results showed that the pres-
ence of plasma potentiated menadione-induced hemolysis
mediated by non-enzymatic reaction with protein thiols. It is
therefore recommended that investigators of drug toxicity,
especially toxicity of quinones, give consideration to the fact
that their drugs may be more toxic in vivo, due to the pres-
ence of plasma. They should therefore consider also assessing
in vitro cytotoxicity in the presence of plasma. Such experi-
ments are complicated in most cell or tissue systems, but rel-
atively simple in a platelet and plasma system such as we used
in this study.
Blood plasma has various antioxidant biomolecules which
can protect the vascular endothelial cells, blood cells, and
circulating lipids and proteins from both endogenous and
exogenous sources of oxidative damage [14]. Previously it
was reported that plasma could inhibit cell damage by oxida-
tive stress due to the antioxidant capacity of plasma [27]. This
is due to the presence of soluble antioxidants such as ascor-
bate, K-tocopherol, and pyruvate, as well as ceruloplasmin
and transferrin, which bind metal and therefore block the
formation of more reactive free radicals [14]. In contrast, we
have observed that menadione-induced cytotoxicity to plate-
lets is actually potentiated in the presence of plasma. We
believe that this occurs due to the generation of reactive oxy-
gens from the non-enzymatic reaction of menadione with pro-
tein thiols in the plasma ultimately exceeding the antioxidant
capacity of plasma. This means that plasma itself may be a
primary target of menadione cytotoxicity.
This premise is supported by our observations that sudden
and rapid decreases in plasma thiols occurred due to mena-
dione (Fig. 2). Plasma thiols have antioxidant capacity [28]
and their depletion could be related to such diseases as rheu-
matoid arthritis [29] and congestive heart failure [30]. In ad-
dition to decreasing plasma thiols, the reactive oxygens
formed by menadione can lower soluble antioxidants such
as ascorbate, so it is likely that menadione decreases the total
plasma antioxidant capacity.
In summary, this study has demonstrated that protein thiols
in plasma react non-enzymatically with menadione to generate
reactive oxygens, which directly lead to potentiated cellular
injury to a type of cell (platelets). So far, plasma has been
known to decrease the pharmacological e¡ects of many drugs.
Since our study suggests that plasma may also enhance the
toxicity of a model quinone (menadione), attention should be
paid to this possibility for quinones and some other drugs.
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